Equities

Mainz Biomed NV

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Mainz Biomed NV

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.6186
  • Today's Change-0.057 / -8.41%
  • Shares traded227.60k
  • 1 Year change-89.69%
  • Beta0.3464
Data delayed at least 15 minutes, as of Feb 18 2026 16:15 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

  • Revenue in USD (TTM)659.94k
  • Net income in USD-18.97m
  • Incorporated2021
  • Employees19.00
  • Location
    Mainz Biomed NVSirius Gutenberg ParkRobert-Koch-Strasse 50MAINZ 55129GermanyDEU
  • Phone+49 6 131265140
  • Websitehttps://www.mainzbiomed.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ethema Health Corp15.42m-1.44m2.32m70.00------0.1503-0.0002-0.00020.002-0.00110.7242--10.95220,280.00-6.761.79-14.20-------9.343.51--0.0032.68--12.5875.64-282.77---8.75--
Aesthetic Medical Intl Hldg Grp Ltd(ADR)107.54m-1.16m2.92m1.31k----0.39720.0272-0.0213-0.02132.18--1.4728.5274.3982,155.05-2.45-30.31-10.38-77.3144.1450.05-1.67-28.930.20544.300.9902--10.71-2.7646.72---16.53--
Advanced Biomed Inc0.00-3.38m5.56m31.00--1.72-----0.1598-0.15980.000.13880.00----0.00-63.08---154.97-------------9.330.00-------17.13------
Mangoceuticals Inc466.92k-20.12m5.85m----0.3354--12.52-3.03-3.030.0651.130.0298-------126.57---136.09--60.62---4,245.42------0.0063---15.81--5.50------
Mainz Biomed NV659.94k-18.97m6.12m19.00--1.10--9.27-10.37-10.370.29190.61640.07230.41914.3434,733.68-207.82-162.37-1,682.32-250.3067.5046.23-2,874.67-2,554.690.4314-26.810.4366---0.166426.0117.66------
CompuMed Inc1.78m-151.00k6.24m8.00--49.08--3.51-0.1337-0.13371.580.09972.3836.714.83---19.92-46.77-48.38-76.7850.4257.04-8.38-25.840.9493-2.930.7744---1.73-5.7164.41---18.75--
Univec Inc-100.00bn-100.00bn6.31m3.00---------------0.0113-----------50.96------17.47---198.310.0051-------74.07-64.8336.83------
Xcelerate Inc3.96m-296.19k6.78m1.00--4.85--1.71-0.0014-0.00140.01890.00321.516.133.90---11.334.24-49.19--71.7174.10-7.481.930.4797-0.82180.7237--6.6310.4317.00--174.06--
Biocorrx Inc948.36k-5.16m7.11m5.00------7.49-0.3254-0.32540.0602-0.6680.232--1.49---104.32-370.28----62.1767.86-449.74-4,584.390.0869-5.40-----91.40-49.79-35.55------
Interpace Biosciences Inc41.82m4.64m8.08m111.0065.58--1.540.19310.0278-0.00351.53-0.06733.2112.756.31376,747.8039.18-21.04750.62-42.3164.5755.7412.21-16.711.3524.131.44--17.2114.14186.31--46.23--
Data as of Feb 18 2026. Currency figures normalised to Mainz Biomed NV's reporting currency: US Dollar USD

Institutional shareholders

8.19%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 30 Sep 2025394.52k4.35%
Cerity Partners LLCas of 31 Dec 2025163.25k1.80%
UBS Securities LLCas of 31 Dec 202554.18k0.60%
Dauntless Investment Group LLCas of 30 Sep 202551.00k0.56%
Steward Partners Investment Advisory LLCas of 31 Dec 202530.00k0.33%
Jane Street Capital LLCas of 31 Dec 202518.44k0.20%
Journey Advisory Group LLCas of 31 Dec 202515.00k0.17%
Citigroup Global Markets, Inc. (Investment Management)as of 31 Dec 202512.30k0.14%
Osaic Wealth, Inc. (Investment Management)as of 30 Sep 20252.11k0.02%
Provenance Wealth Advisors LLCas of 31 Dec 20251.17k0.01%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.